This site is best experienced with JavaScript enabled.

KYNMOBI (apomorphine hydrochloride) sublingual film is a prescription medicine used to treat short-term (acute), intermittent OFF episodes in people with Parkinson’s disease (PD).1

It is not known if KYNMOBI is safe and effective in children.

Now Approved

The FIRST AND ONLY sublingual treatment for OFF episodes in Parkinson's disease

KYNMOBI (apomorphine hydrochloride) sublingual film is a prescription medicine used to treat short-term (acute), intermittent OFF episodes in people with Parkinson’s disease (PD).1

It is not known if KYNMOBI is safe and effective in children.

AVAILABLE
SEPTEMBER 2020

SIGN UP FOR UPDATES

Register to receive updates about the first and only sublingual film, prescription medicine used to treat OFF episodes associated with Parkinson's disease.

I am a...

*Required field

Sunovion Pharmaceuticals Inc. respects your information.

*

Please see the most recent version of our privacy policy, which may change from time to time.

To be removed from our mailing list, please visit our unsubscribe page or call 1-844-596-6624.

Sunovion Answers Logo

For More information,
call Sunovion Answers

1-844-596-6624

Important Safety Information and Indication for KYNMOBI (apomorphine hydrochloride) SUBLINGUAL FILM

Do not take KYNMOBI if you are taking certain medicines to treat nausea called 5HT3 antagonists, including ondansetron, granisetron, dolasetron, palonosetron, and alosetron. People taking ondansetron together with apomorphine, the active ingredient in KYNMOBI, have had very low blood pressure and lost consciousness or “blacked out.”

Thank you for registering at KYNMOBI.com!

We look forward to telling you more about KYNMOBI, a new medication to treat OFF episodes associated with Parkinson's disease, as it becomes available.

You have been successfully unsubscribed.

Please allow 7-10 days to process your request.